These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

249 related items for PubMed ID: 22050392

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Health Care Resource Utilization and Costs Among Newly Diagnosed and Oral Anticoagulant-Naive Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the United States.
    Jain R, Fu AC, Lim J, Wang C, Elder J, Sander SD, Tan H.
    J Manag Care Spec Pharm; 2018 Jan; 24(1):73-82. PubMed ID: 29290177
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Comparison of all-cause, stroke, and bleed-specific healthcare resource utilization among patients with non-valvular atrial fibrillation (NVAF) and newly treated with dabigatran or warfarin.
    Song X, Gandhi P, Gilligan AM, Arora P, Wang C, Henriques C, Sander S, Smith DM.
    Expert Rev Pharmacoecon Outcomes Res; 2019 Apr; 19(2):213-222. PubMed ID: 28649894
    [Abstract] [Full Text] [Related]

  • 6. Effect of Anticoagulation on Hospitalization Costs After Intracranial Hemorrhage in Atrial Fibrillation: A Registry Study.
    Vestergaard AS, Skjøth F, Lip GY, Larsen TB.
    Stroke; 2016 Apr; 47(4):979-85. PubMed ID: 26883499
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Comparison of stroke- and bleed-related healthcare resource utilization and costs among patients with newly diagnosed non-valvular atrial fibrillation and newly treated with dabigatran, rivaroxaban, or warfarin.
    Gilligan AM, Franchino-Elder J, Song X, Wang C, Henriques C, Sainski-Nguyen A, Wilson K, Smith DM, Sander S.
    Expert Rev Pharmacoecon Outcomes Res; 2019 Apr; 19(2):203-212. PubMed ID: 30251553
    [Abstract] [Full Text] [Related]

  • 9. Retrospective study of total healthcare costs associated with chronic nonvalvular atrial fibrillation and the occurrence of a first transient ischemic attack, stroke or major bleed.
    Boccuzzi SJ, Martin J, Stephenson J, Kreilick C, Fernandes J, Beaulieu J, Hauch O, Kim J.
    Curr Med Res Opin; 2009 Dec; 25(12):2853-64. PubMed ID: 19916729
    [Abstract] [Full Text] [Related]

  • 10. Major bleed costs of atrial fibrillation patients treated with factor Xa inhibitor anticoagulants.
    Fermann GJ, Lovelace B, Christoph MJ, Lingohr-Smith M, Lin J, Deitelzweig SB.
    J Med Econ; 2020 Dec; 23(12):1409-1417. PubMed ID: 33054507
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization.
    Bullano MF, Willey V, Hauch O, Wygant G, Spyropoulos AC, Hoffman L.
    J Manag Care Pharm; 2005 Oct; 11(8):663-73. PubMed ID: 16194130
    [Abstract] [Full Text] [Related]

  • 13. Risk of hemorrhage and treatment costs associated with warfarin drug interactions in patients with atrial fibrillation.
    Suh DC, Nelson WW, Choi JC, Choi I.
    Clin Ther; 2012 Jul; 34(7):1569-82. PubMed ID: 22717419
    [Abstract] [Full Text] [Related]

  • 14. Incremental economic burden associated with major bleeding among atrial fibrillation patients treated with factor Xa inhibitors.
    Deitelzweig S, Neuman WR, Lingohr-Smith M, Menges B, Lin J.
    J Med Econ; 2017 Dec; 20(12):1217-1223. PubMed ID: 28760063
    [Abstract] [Full Text] [Related]

  • 15. Use of resources and cost implications of stroke prophylaxis with warfarin for patients with nonvalvular atrial fibrillation.
    Abdelhafiz AH, Wheeldon NM.
    Am J Geriatr Pharmacother; 2003 Dec; 1(2):53-60. PubMed ID: 15555467
    [Abstract] [Full Text] [Related]

  • 16. Effect of Apixaban Versus Warfarin Use on Health Care Resource Utilization and Costs Among Elderly Patients with Nonvalvular Atrial Fibrillation.
    Deitelzweig S, Luo X, Gupta K, Trocio J, Mardekian J, Curtice T, Lingohr-Smith M, Menges B, Lin J.
    J Manag Care Spec Pharm; 2017 Nov; 23(11):1191-1201. PubMed ID: 29083968
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effect of rivaroxaban versus warfarin on health care costs among nonvalvular atrial fibrillation patients: observations from rivaroxaban users and matched warfarin users.
    Laliberté F, Cloutier M, Crivera C, Nelson WW, Olson WH, Schein J, Vanderpoel J, Germain G, Lefebvre P.
    Adv Ther; 2015 Mar; 32(3):216-27. PubMed ID: 25784509
    [Abstract] [Full Text] [Related]

  • 20. Discontinuation/Interruption of Warfarin Therapy in Patients with Nonvalvular Atrial Fibrillation.
    Spivey CA, Qiao Y, Liu X, Mardekian J, Parker RB, Phatak H, Claflin AB, Kachroo S, Abdulsattar Y, Chakrabarti A, Wang J.
    J Manag Care Spec Pharm; 2015 Jul; 21(7):596-606. PubMed ID: 26108384
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.